Please check your internet connection and try again.
# Tab%2525252525252525252525252525252525252525252525252525252525252525252525252520voihep
## Overview
Tab%2525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a nucleoside analog used in the treatment of chronic hepatitis B virus (HBV) infection.
## Primary Indications
* Chronic hepatitis B virus (HBV) infection in adults and pediatric patients.
## Adult Dosing
* The recommended dose is 0.5 mg orally once daily.
## Pediatric Dosing
* For pediatric patients aged 12 years and older and weighing at least 35 kg: The recommended dose is 0.5 mg orally once daily.
* Data for pediatric patients younger than 12 years or weighing less than 35 kg is limited.
## Dose Adjustments
* **Renal Impairment:** Dose reduction is recommended based on creatinine clearance (CrCl).
* CrCl 30-49 mL/min: 0.5 mg every other day.
* CrCl 10-29 mL/min: 0.5 mg twice weekly.
* CrCl <10 mL/min or on hemodialysis/continuous ambulatory peritoneal dialysis: 0.5 mg twice weekly.
* **Hepatic Impairment:** No dose adjustment is typically required in patients with hepatic impairment. However, caution is advised in patients with decompensated cirrhosis.
## Contraindications
* Hypersensitivity to tenofovir alafenamide or any component of the formulation.
## Adverse Effects
* **Common:** Nausea, diarrhea, headache, abdominal pain, rash.
* **Serious:** Lactic acidosis, severe hepatomegaly with steatosis, immune reconstitution inflammatory syndrome (IRIS), renal toxicity, bone mineral density reduction.
## Key Drug Interactions
* **Strong CYP3A4 Inducers:** May decrease plasma concentrations of tenofovir alafenamide (e.g., rifampin, carbamazepine, phenytoin).
* **Antiretroviral Agents:** Concurrent use with certain HIV medications may require dose adjustments or monitoring. Consult specific drug interaction resources.
## Monitoring
* **Baseline and Periodic:** Renal function (serum creatinine, eGFR), liver function tests (ALT, AST, bilirubin), HBV DNA levels.
* **Baseline and Periodic:** Bone mineral density may be considered in patients with a history of fractures or other risk factors for osteoporosis.
## Clinical Pearls
* Tab%2525252525252525252525252525252525252525252525252525252525252525252525252520voihep is a prodrug of tenofovir, offering improved intracellular delivery and lower systemic exposure compared to other tenofovir formulations, potentially leading to a better renal and bone safety profile.
* Treatment should be guided by a healthcare professional experienced in managing chronic HBV infection.
* Discontinuation of treatment may lead to HBV flare; therefore, consider careful monitoring after cessation.
***
**Disclaimer:** This information is intended for clinical professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and clinical guidelines before making any treatment decisions.
